191 patents
Page 3 of 10
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
8 Dec 22
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 3 Aug 22
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
8 Dec 22
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 3 Aug 22
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
8 Dec 22
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 3 Aug 22
Utility
Restimulation of Cryopreserved Tumor Infiltrating Lymphocytes
8 Dec 22
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 11 Aug 22
Utility
Gene Editing of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
8 Dec 22
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Cecile Chartier-Courtaud, Krit Ritthipichai
Filed: 23 Oct 20
Utility
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
6 Dec 22
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 1 Jul 22
Utility
Restimulation of Cryopreserved Tumor Infiltrating Lymphocytes
1 Dec 22
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 11 Aug 22
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
1 Dec 22
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 1 Jul 22
Utility
Restimulation of Cryopreserved Tumor Infiltrating Lymphocytes
1 Dec 22
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 31 May 22
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
17 Nov 22
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 3 Aug 22
Utility
Processes for Generating Til Products Enriched for Tumor Antigen-specific T-cells
27 Oct 22
The present invention provides improved and/or shortened processes and methods for reprogramming TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy.
Cecile CHARTIER-COURTAUD, Krit RITTHIPICHAI
Filed: 4 May 22
Utility
Expansion of TILs from Cryopreserved Tumor Samples
13 Oct 22
Methods of expanding tumor infiltrating lymphocytes (TILs) from cryopreserved tumor tissue and methods of using the expanded TILs in the treatment of human diseases, including cancers, are disclosed.
Anand Veerapathran, Kenneth Onimus
Filed: 20 Sep 19
Utility
Methods and Compositions for T-cell Coculture Potency Assays and Use with Cell Therapy Products
6 Oct 22
The present invention provides novel processes, compositions, and methods for analyzing or assaying the potency and/or functionality of tumor infiltrating lymphocyte (TIL) products for use in therapy, including human cancer therapy, and analyzing or assaying the potency and/or functionality of other polyclonal products, such as marrow infiltrating lymphocyte (MIL) and peripheral blood lymphocyte (PBL) products.
Michelle R. Simpson-Abelson, Matthew J. Frigault, Wayne P. Rothbaum, Michael Weiser
Filed: 25 Mar 22
Utility
Engineered Artificial Antigen Presenting Cells for Tumor Infiltrating Lymphocyte Expansion
6 Oct 22
In some embodiments, compositions and methods relating to isolated artificial antigen presenting cells (aAPCs) are disclosed, including aAPCs comprising a myeloid cell transduced with one or more viral vectors, such as a MOLM-14 or a EM-3 myeloid cell, wherein the myeloid cell endogenously expresses HLA-A/B/C, ICOS-L, and CD58, and wherein the one or more viral vectors comprise a nucleic acid encoding CD86 and a nucleic acid encoding 4-1BBL and/or OX40L and transduce the myeloid cell to express CD86 and 4-1BBL and/or OX40L proteins.
Anand Veerapathran, Aishwarya Gokuldass, Brian Rabinovich, Michael T. Lotze
Filed: 13 Apr 21
Utility
Engineered Artificial Antigen Presenting Cells for Tumor Infiltrating Lymphocyte Expansion
6 Oct 22
In some embodiments, compositions and methods re¬lating to isolated artificial antigen presenting cells (aAPCs) are dis¬closed, including aAPCs comprising a myeloid cell transduced with one or more viral vectors, such as a MOLM-14 or a EM-3 myeloid cell, wherein the myeloid cell endogenously expresses HLA-A/B/C, ICOS-L, and CD58, and wherein the one or more viral vectors com¬prise a nucleic acid encoding CD86 and a nucleic acid encoding 4-1BBL and/or OX40L and transduce the myeloid cell to express CD86 and 4-1BBL and/or OX40L proteins.
Anand Veerapathran, Aishwarya Gokuldass, Brian Rabinovich, Michael T. Lotze
Filed: 13 Apr 21
Utility
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
6 Sep 22
Methods of treating melanomas refractory to other therapies using tumor infiltrating lymphocytes are disclosed.
Maria Fardis
Filed: 5 Dec 18
Utility
Methods and Compositions for Selecting Tumor Infiltrating Lymphocytes and Uses of the Same In Immunotherapy
11 Aug 22
The present invention provides improved methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for selecting TILs responsive to a mutant polypeptide expressed by cancer cells and not expressed in normal tissue.
Seth Wardell, Maritza Lienlaf Moreno, Cecile Chartier-Courtaud, Lavakumar Karyampudi
Filed: 12 May 20
Utility
Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
2 Aug 22
In some embodiments, methods of delivering a therapeutically effective amount of an expanded number of tumor infiltrating lymphocytes obtained from tumor remnants to a patient in need thereof, for the treatment of a cancer, are disclosed.
Michelle R. Simpson-Abelson, Christopher Mosychuk, Michael T. Lotze
Filed: 17 Nov 17
Utility
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
12 Jul 22
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Cecile Chartier-Courtaud, Krit Ritthipichai
Filed: 28 Jul 21
Utility
Processes for Generating Til Products Enriched for Tumor Antigen-specific T-cells
30 Jun 22
The present invention provides improved and/or shortened processes and methods for reprogramming TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy.
Cecile Chartier-Courtaud, Krit Ritthipichai
Filed: 8 Jan 19